Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,434 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combination of pimitespib (TAS-116) with sunitinib is an effective therapy for imatinib-resistant gastrointestinal stromal tumors.
Teranishi R, Takahashi T, Obata Y, Nishida T, Ohkubo S, Kazuno H, Saito Y, Serada S, Fujimoto M, Kurokawa Y, Saito T, Yamamoto K, Yamashita K, Tanaka K, Makino T, Nakajima K, Hirota S, Naka T, Eguchi H, Doki Y. Teranishi R, et al. Among authors: saito t, saito y. Int J Cancer. 2023 Jun 15;152(12):2580-2593. doi: 10.1002/ijc.34461. Epub 2023 Feb 21. Int J Cancer. 2023. PMID: 36752576
Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma.
Harada E, Serada S, Fujimoto M, Takahashi Y, Takahashi T, Hara H, Nakatsuka R, Sugase T, Nishigaki T, Saito Y, Hiramatsu K, Nojima S, Mitsuo R, Ohkawara T, Morii E, Mori M, Doki Y, Kaneda Y, Naka T. Harada E, et al. Among authors: saito y. Oncotarget. 2017 Apr 11;8(15):24741-24752. doi: 10.18632/oncotarget.15799. Oncotarget. 2017. PMID: 28445969 Free PMC article.
SOCS1 gene therapy has antitumor effects in imatinib-resistant gastrointestinal stromal tumor cells through FAK/PI3 K signaling.
Sugase T, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Hiramatsu K, Nishida T, Hirota S, Saito Y, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Nakajima K, Hanasaki K, Kishimoto T, Mori M, Doki Y, Naka T. Sugase T, et al. Among authors: saito y. Gastric Cancer. 2018 Nov;21(6):968-976. doi: 10.1007/s10120-018-0822-1. Epub 2018 Apr 5. Gastric Cancer. 2018. PMID: 29623544
Lipolysis-stimulated lipoprotein receptor overexpression is a novel predictor of poor clinical prognosis and a potential therapeutic target in gastric cancer.
Sugase T, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Hiramatsu K, Koh M, Saito Y, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Nakajima K, Hanazaki K, Mori M, Doki Y, Naka T. Sugase T, et al. Among authors: saito y. Oncotarget. 2018 Aug 31;9(68):32917-32928. doi: 10.18632/oncotarget.25952. eCollection 2018 Aug 31. Oncotarget. 2018. PMID: 30250639 Free PMC article.
TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours.
Saito Y, Takahashi T, Obata Y, Nishida T, Ohkubo S, Nakagawa F, Serada S, Fujimoto M, Ohkawara T, Nishigaki T, Sugase T, Koh M, Ishida T, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Nakajima K, Yamasaki M, Hirota S, Naka T, Mori M, Doki Y. Saito Y, et al. Br J Cancer. 2020 Mar;122(5):658-667. doi: 10.1038/s41416-019-0688-y. Epub 2019 Dec 20. Br J Cancer. 2020. PMID: 31857719 Free PMC article.
Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer.
Nishigaki T, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Hara H, Sugase T, Otsuru T, Saito Y, Tsujii S, Nomura T, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Nakajima K, Eguchi H, Yamasaki M, Mori M, Doki Y, Naka T. Nishigaki T, et al. Among authors: saito y. Br J Cancer. 2020 Apr;122(9):1333-1341. doi: 10.1038/s41416-020-0781-2. Epub 2020 Mar 10. Br J Cancer. 2020. PMID: 32152502 Free PMC article.
Correction: Lipolysis-stimulated lipoprotein receptor overexpression is a novel predictor of poor clinical prognosis and a potential therapeutic target in gastric cancer.
Sugase T, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Hiramatsu K, Koh M, Saito Y, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Nakajima K, Hanazaki K, Mori M, Doki Y, Naka T. Sugase T, et al. Among authors: saito y. Oncotarget. 2021 Oct 12;12(21):2232-2233. doi: 10.18632/oncotarget.28096. eCollection 2021 Oct 12. Oncotarget. 2021. PMID: 34676057 Free PMC article.
9,434 results